| Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. | |
| | |
MedLine Citation:
|
PMID: 19931584 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Growth hormone-releasing peptides (GHRP) and ghrelin are synthetic and natural ligands of growth hormone secretagogue receptor (GHSR) respectively and are shown to exert protective actions on cardiac dysfunction. Because ghrelin has been reported to inhibit proinflammatory responses in human endothelium and GHSR has been identified in blood vessels, we hypothesized that GHRP could alleviate the development of atherosclerosis (As). Atherosclearosis was induced by a short period (4 days) of vitamin D(3) and chronic (three months) intragastric feeding of high fat emulsion (containing 0.5% propylthiouracil) in adult SD rats. Some As rats received chronic hexarelin (a variant of GHRP) injection (SC BID, 30 days) and normal rats received placebo as control. Significant atherosclerosis developed in animals fed with the emulsion. Serum total cholesterol and LDL-c increased, and HDL-c and aortic nitric oxide (NO) decreased significantly in As group. Hexarelin suppressed the formation of atherosclerotic plaques and neointima, partially reversed serum HDL-c/LDL-c ratio and increased the levels of serum NO and aortic mRNAs of eNOS, GHSR and CD36 in As rats. Hexarelin also decreased [(3)H]-TdR incorporation in cultured vascular smooth muscle cell (VSMC) and calcium sedimentation in aortic wall. Furthermore, foam cell formation induced by ox-LDL was decreased by hexarelin. In conclusion, hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in rats, possibly through upregulating HDL-c/LDL-c ratio, vascular NO production and downregulating the VSMC proliferation, aortic calcium sedimentation and foam cell formation. These novel anti-atherosclerotic actions of hexarelin suggest that the peptide might have a clinical potential in treating atherosclerosis. |
| | |
Authors:
|
Jinjiang Pang; Qihua Xu; Xiangbin Xu; Hongchao Yin; Rongkun Xu; Shu Guo; Wei Hao; Luya Wang; Chen Chen; Ji-Min Cao |
Related Documents
:
|
8929254 - Development of an avian model for restenosis. 6882504 - Anti-proliferative effect of pyridinolcarbamate and of aspirin in the early stages of a... 8642434 - Prevention of atherosclerosis with dietary antioxidants: fact or fiction? 9712334 - Experimental hypercholesterolemia induces ultrastructural changes in the internal elast... 6858954 - Evaluation of body composition and nitrogen content of renal patients on chronic dialys... 15113954 - Lymphatic fat absorption varies among rats administered dairy products differing in phy... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-11-30 |
Journal Detail:
|
Title: Peptides Volume: 31 ISSN: 1873-5169 ISO Abbreviation: Peptides Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-03-12 Completed Date: 2010-07-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8008690 Medline TA: Peptides Country: United States |
Other Details:
|
Languages: eng Pagination: 630-8 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2009 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Physiology, School of Basic Medicine, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, 5 Dong Dan San Tiao, Beijing 100005, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Aorta / metabolism, pathology Atherosclerosis / chemically induced*, drug therapy*, pathology Cholecalciferol / pharmacology* Dietary Fats / adverse effects* Female Ghrelin / metabolism Humans Lipoproteins / blood Male Muscle, Smooth, Vascular / cytology, drug effects Nitric Oxide / metabolism Nitric Oxide Synthase Type III / genetics, metabolism Oligopeptides / therapeutic use* Random Allocation Rats Rats, Sprague-Dawley |
| Chemical | |
Reg. No./Substance:
|
0/Dietary Fats; 0/Ghrelin; 0/Lipoproteins; 0/Oligopeptides; 10102-43-9/Nitric Oxide; 140703-51-1/hexarelin; 67-97-0/Cholecalciferol; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 1.14.13.39/Nos3 protein, rat |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antimicrobial mechanism of pore-forming protegrin peptides: 100 pores to kill E. coli.
Next Document: Clinician-rated functioning and patient-rated quality of life in schizophrenia: Implications of thei...